Fenwick Represents DexCare in $75 Million Series C Financing

Fenwick represented DexCare, a patient demand and care access platform, in its $75 million Series C financing. The new funding brings the total raised to $146 million, including two oversubscribed rounds closed in less than two years. The round was led by ICONIQ Growth with participation from existing partners Transformation Capital, Kaiser Permanente Ventures, Define Ventures, Frist Cressey Ventures and SpringRock Ventures.

The funding will advance DexCare’s platform, which extends limited health-system capacity to serve patients faster and to precisely manage the supply and demand of digital-care access. More information can be obtained from the company’s announcement.

The transaction was led by corporate partner Michael Esquivel, counsel Khang Tran and associate Kasey Wang.